- Home
- BYAH vs VRAX Comparison
BYAH vs VRAX Comparison
Compare BYAH & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BYAH | VRAX |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3M | 2.3M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BYAH | VRAX |
|---|---|---|
| Price | $2.60 | $2.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | ★ 827.0K | 463.1K |
| Earning Date | 03-02-2026 | 06-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.05 | $0.10 |
| 52 Week High | $6.64 | $13.19 |
Technical Indicators
Market Signals| Indicator | BYAH | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 56.51 | 43.08 |
| Support Level | $2.58 | $2.55 |
| Resistance Level | $2.77 | $3.10 |
| Average True Range (ATR) | 0.25 | 0.30 |
| MACD | -0.11 | -0.06 |
| Stochastic Oscillator | 5.43 | 2.27 |
Price Performance
Historical ComparisonAbout BYAH Park Ha Biological Technology Co. Ltd. Ordinary Shares
Park Ha Biological Technology Co Ltd is engaged in developing its private skincare label, direct skincare products sales, and franchise alliances promotions. Its Park Ha brand focuses on providing solutions for problematic skin. The company's Operating Subsidiaries provide skincare and cosmetic products under its brand, Park Ha, in China. Its Operating Subsidiaries develop its proprietary beauty products and offer complementary after-sales beauty services in its physical stores.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.